Bioporto AS (FRA:2P4) Loans Receivable: €0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:2P4 Bioporto AS FRA:2P4
69 GF Score
Price €0.14
GF Value €0.13
! 4 Warning Signs
View Full Analysis

What is Bioporto AS Loans Receivable?

Bioporto AS FRA:2P4 -1.06% 69 Loans Receivable is €0.00 Mil as of Dec. 2025. GuruFocus rates FRA:2P4 with a GF Score™ of 69/100 and a GF Value™ of €0.13. The stock has 4 warning signs investors should review.

Bioporto AS's Loans Receivable for the quarter that ended in Dec. 2025 was €0.00 Mil.

Bioporto AS Loans Receivable Historical Data

* Premium members only.

The historical data trend for Bioporto AS's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bioporto AS Loans Receivable Chart

Bioporto AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Loans Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Bioporto AS Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:2P4
69GF Score
Bioporto AS FRA:2P4
Loans Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bioporto AS Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.

Frequently Asked Questions Learn more about Loans Receivable →
What does a Loans Receivable of €0.00 Mil mean?
Bioporto AS (FRA:2P4) has a Loans Receivable of €0.00 Mil as of Dec. 2025. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Bioporto AS and its competitors.
Is Bioporto AS's Loans Receivable too high?
Bioporto AS's current Loans Receivable is €0.00 Mil. Overall, Bioporto AS has a GF Score™ of 69/100, reflecting its overall financial health beyond just this single metric.
How does Bioporto AS's Loans Receivable compare to TMO and DHR?
Bioporto AS's Loans Receivable of €0.00 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Loans Receivable for a Medical Diagnostics & Research company?
A good Loans Receivable depends on the Medical Diagnostics & Research industry context. However, Loans Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Loans Receivable mean?
A high Loans Receivable can signal that a stock is expensive relative to its fundamentals. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Bioporto AS and its competitors. Bioporto AS's current Loans Receivable is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioporto AS stock overvalued right now?
Bioporto AS (FRA:2P4) has a current Loans Receivable of €0.00 Mil. The stock's GF Value™ is €0.13, compared to a current price of €0.14 — trading 8.1% above its estimated fair value. The current Loans Receivable is €0.00 Mil. Bioporto AS's overall GF Score™ is 69/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Loans Receivable calculated?
Loans Receivable is calculated from a company's financial statements. For Bioporto AS (FRA:2P4), the current Loans Receivable is €0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bioporto AS (FRA:2P4) Overvalued in 2026?

Based on GuruFocus' analysis, Bioporto AS stock appears to be overvalued. The current stock price of €0.14 is trading 8.1% above its estimated GF Value™ of €0.13.

Key valuation signals for FRA:2P4:

  • Loans Receivable: €0.00 Mil
  • GF Value™: €0.13 vs. price of €0.14 (8.1% above fair value)
  • GF Score™: 69/100 with 4 warning signs

No single metric tells the full story. See the FRA:2P4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bioporto AS Business Description

Other Exchanges BIOPOR:Denmark
Address Tuborg Havnevej 15, Ground Floor, Hellerup, DNK, DK-2900
Bioporto AS is an in-vitro diagnostic company. The company provides healthcare professionals in clinical and research settings with a range of diagnostic tests and antibodies. Its product portfolio consists of specialized monoclonal antibodies and antibody-based diagnostic assays, used in the treatment of critically ill patients. The company's products include the NGAL Test, ELISA kits, Antibodies, and Other products and licenses. Geographically, it derives a majority of its revenue from North America. Geographically, its business area is in North America, Denmark, and rest of Europe, and Asia. The products of the company involve: ProNephro AKI, The NGAL Test, Antibodies, ELISA Kits, gRad Lateral Flow, and others.
69GF Score

Get the complete analysis for FRA:2P4

Loans Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.14
Price
€0.13
GF Value